We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Belul
Shifa
belul.shifa@gstt.nhs.uk
Prof
Anand David
Purushotham
arnie.purushotham@kcl.ac.uk
Belul
Shifa
belul.shifa@gstt.nhs.uk
Malignant neoplasm of breast
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Magnetic Resonance Imaging (MRI) is a type of imaging used to delineate breast cancers to determine the type of surgery needed. However, more commonly it is used as an imaging marker to assess whether chemotherapy has its desired effect of shrinking the tumour. Unfortunately, the MRI can only assess the changes in the tumour after several months of chemotherapy This specific project is looking at a novel MRI method called Magnetic Resonance Force (MRF). MRF has been developed to measure how stiff the tissue around the tumour in the breast by measuring the Interstitial Fluid Pressure (IFP). The aim of this research is to test this new imaging technique in three cohorts of patients; two of which are suffering from breast cancer.
1. Healthy Volunteers 2
2. Patient undergoing surgery as first line of their treatment for their breast cancer
3. Patients undergoing chemotherapy as first line of their treatment for their breast cancers Healthy Volunteers will be recruited in order to establish MRF hardware imaging acquisition protocols for the next phase. In patients undergoing surgery as first line of treatment for their breast cancer,if proven useful, these scan would enable doctors to outline the tumour in the breast more accurately, therefore assisting the breast surgeon with the surgery and potentially eliminating the need of sentinel lymph node biopsy. In patients undergoing chemotherapy as first line of treatment for their breast cancer, this imaging method these scans would enable doctors to identify those women in whom chemotherapy was not working at an early stage. This would prevent unnecessary side effects and allow a rapid change to other treatments in that particular patient. MRF scans may also help test the usefulness of new therapies in the future. This would speed up development of new and better treatments for women with breast cancer.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Interventional type: Imaging;
You can take part if:
You may not be able to take part if:
PHASE I: Healthy Volunteers recruited from Guy's and St.Thomas' NHS Foundation Trust/King's College London only: Contraindications for MRI such as: • cardiac pacemaker • metallic implants • major claustrophobia • pregnancy or breastfeeding • Inability to provide written informed consent PHASE II STAGE I AND II: Patients undergoing primary surgery or neoadjuvant (pre-operative) treatment: • Contraindications for MRI such as: • cardiac pacemaker • metallic implants • major claustrophobia • prior breast cancer treatment • pregnancy or breastfeeding • known allergy against the contrast agent (gadolinium chelate) and renal failure • Inability to provide written informed consent
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Belul
Shifa
belul.shifa@gstt.nhs.uk
Belul
Shifa
belul.shifa@gstt.nhs.uk
Prof
Anand David
Purushotham
arnie.purushotham@kcl.ac.uk
The study is sponsored by King's College London and funded by European Commission .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 33254
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
